Navigation Links
New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
Date:9/19/2008

he level of disability at the start of treatment and cognitive function 16 years later. More research is needed to determine how treatment might benefit long-term cognitive outcome," said Dr. Goodin.

"The data presented here underscore the need to help patients start therapy earlier and stay on treatment for the long-term," said, Ludger Heeck, Ph.D. Vice President and General Manager, Specialty Medicine Bayer HealthCare Pharmaceuticals Inc. "Bayer is committed to helping provide both the medication and the support services that people need to help treat their MS. We pioneered the concept of customized MS support services, and our best-in-class BETAPLUS(TM) program goes far beyond treatment to offer a wide range of beneficial services for people with MS. From having dedicated MS nurses who can provide practical help and advice, to offering product enhancements like our new thinnest needle and optional autoinjector that can help make injection administration more comfortable, we continue to lead the way in helping people with MS start on and stay on treatment."

About the Trials

The 16-Year Long-term Follow-up Study is a multicenter observational study that collected data from patients with relapsing-remitting MS (RRMS) who participated in the pivotal North American trials for Betaseron. Several statistical methods were used to assess patient data and examine the relationship between timing of drug exposure and long-term outcomes. Drug exposure was measured as the medication possession ratio (MPR) defined as the actual time the patient received therapy divided by the total time possible before a negative outcome was reached (or at data censor). A statistical method called recursive partitioning was then used to divide treatment groups into "high" or "low" exposure and to determine the relationship between length of drug exposure and long-term outcomes. The use of MPR reduces the bias introduced in long-term trials by the tendency of patients who ar
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
2. Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
3. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
4. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
5. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
6. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
7. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
8. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
11. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
(Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm ... Lawsuits (case #59776/2014), announces they have launched a new ... the popular hair dye, Just For Men, has caused some ... and other areas. In addition to detailing symptoms that are ... the advertisements being run by Wright & Schulte LLC will ...
(Date:7/12/2014)... Beach, FL (PRWEB) July 12, 2014 ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of ... 2014 Quinceanera dresses . The company’s new items ... fashionable without paying a large amount of money. They ... off. , The company’s online shop has become a ... occasion outfits. In addition to exquisite Quinceanera dresses, it ...
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
Breaking Medicine News(10 mins):Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2
... commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) is so potent. ... University School of Medicine, is reported online today by ... the July 2 print issue. ,It had ... cells in the intestine from absorbing cholesterol. The new ...
... Louis researchers have identified common DNA variations that ... of the eight genetic alterations the scientists identified ... vaccination. A few, however, reduced fever risk. ... same genetic variations linked to fever following smallpox ...
... to scientist at annual conference of the European Society ... abnormal can undergo chromosomal modifications. , ... Maternity Hospital, Tel Aviv Sourasky Medical Centre, Tel Aviv, ... meant that the results of preimplantation genetic screening (PGS) ...
... For many decades, medical research studies focused primarily on ... applied to women. But we now know that the ... women are more than skin deep. Beginning in 1990, ... based advocacy organization, conveyed to a national audience the ...
... and their friends filled the area in and around the ... 14th annual Komen Puget Sound Race for the Cure . ... cancer, while many others were running to honor family members ... in the pink T-shirts and sporting the medallions awarded by ...
... much as $2.7 billion a year, according to the Access ... of Crohn's disease and ulcerative colitis. Crohn's disease is a ... ulcerations (breaks in the lining) of the small and large ... mouth to the anus. It is named after the physician ...
Cached Medicine News:Health News:Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 2Health News:Genetic Variations Leads to Fever After Smallpox Vaccination 3Health News:Preimplanted Genetic Screening Should Be Interpreted With Caution 2Health News:Rare Womens Lung Disease May Yield Insights Into Common Diseases 2Health News:Annual Cancer Run Draws Huge Response in US 2Health News:Inflamed Intestines Cost Australians Heavily 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: